Does Mounjaro lower blood pressure?
Yes, it can. The more accurate answer is that Mounjaro has been associated with lower average blood pressure in clinical trial populations, but it is not guaranteed to lower blood pressure for every person.
The UK Summary of Product Characteristics for Mounjaro reports that, in placebo-controlled phase 3 studies in adults with type 2 diabetes, tirzepatide led to average reductions in systolic blood pressure of 6 to 9 mmHg and diastolic blood pressure of 3 to 4 mmHg. In SURMOUNT weight-management studies, average reductions were around 7 mmHg systolic and 4 mmHg diastolic. [1]
That matters because blood pressure is one of the main modifiable risk factors for heart attack, stroke, heart failure, kidney disease and vascular dementia. The NHS also notes that lowering blood pressure even by a small amount can reduce the risk of these problems. [3]
This does not mean Mounjaro should be treated like an antihypertensive medicine. If you have high blood pressure, your blood pressure plan still sits with your GP, prescribing clinician or cardiology team. Mounjaro may be part of a wider weight-management and metabolic-health plan, not a replacement for medicines such as ACE inhibitors, calcium-channel blockers, beta-blockers, diuretics or other prescribed blood pressure treatment.
Why might Mounjaro affect blood pressure?
Mounjaro works on two hormone pathways: GIP and GLP-1. In practical terms, it helps regulate appetite, food intake and blood glucose. For many people, this leads to weight loss, and weight loss can reduce the strain on the heart and blood vessels.
Blood pressure is not controlled by weight alone. It is influenced by salt intake, alcohol, smoking, sleep, stress, kidney function, age, ethnicity, genetics, other medicines and existing cardiovascular disease. That is why two people can lose similar amounts of weight but see different blood pressure changes.
The evidence suggests several possible routes by which Mounjaro may improve the cardiovascular risk picture in suitable patients:
- Weight reduction can reduce vascular and cardiac strain.
- Improved blood glucose control can be particularly relevant for people with type 2 diabetes.
- Some trials show improvements in triglycerides and non-HDL cholesterol, although this does not replace lipid-lowering treatment where that is needed. [1]
- In adults with obesity and heart failure with preserved ejection fraction, tirzepatide reduced worsening heart-failure events in the SUMMIT study population, but that evidence applies to a specific group and should not be generalised to every person taking Mounjaro. [1,6]
The key distinction is this: Mounjaro may improve several factors that influence cardiovascular risk, but it is not a general heart-protection medicine for everyone.
Can you take Mounjaro if you have high blood pressure?
Often, yes, but it depends on your overall medical history and current readings. High blood pressure by itself does not automatically rule out Mounjaro. In fact, hypertension is listed in the Mounjaro weight-management indication as one example of a weight-related comorbid condition for adults with a BMI of 27 to under 30. [1]
That does not mean the medicine is automatically suitable. A prescriber still needs to check your BMI, medical history, current medicines, blood pressure control, side-effect risk and whether any symptoms need GP or urgent assessment first.
You should give your prescriber clear information about:
- your most recent blood pressure readings, including home readings if you have them;
- all blood pressure, heart, diabetes, kidney and cholesterol medicines you take;
- any history of heart attack, stroke, heart failure, arrhythmia, fainting, chest pain or severe dizziness;
- any recent vomiting, diarrhoea, dehydration or reduced fluid intake;
- whether your GP or hospital team is actively changing your cardiovascular medicines.
If your blood pressure is very high, unstable, symptomatic, or being investigated, your prescriber may ask you to speak to your GP before starting or continuing treatment. That is not a delay for the sake of it; it is part of making sure the treatment is being used safely.
Mounjaro and blood pressure medicines
Many people asking about Mounjaro and high blood pressure are really asking a more practical question: “Can I take Mounjaro with blood pressure tablets?” In many cases, people using weight-management medication also take medication for hypertension, cholesterol, diabetes or cardiovascular risk. That does not automatically prevent treatment, but it does make the assessment more important.
The main issue is that blood pressure may fall as weight changes, eating changes or fluid intake changes. Mounjaro can also cause gastrointestinal side effects such as nausea, vomiting, diarrhoea and constipation. The MHRA warns that vomiting and diarrhoea can lead to dehydration, which can sometimes cause serious complications. [2]
If you take blood pressure tablets and then develop dizziness, faintness, palpitations, dehydration, repeated vomiting or unusually low home blood pressure readings, you should contact your GP, prescriber or NHS 111 depending on severity. Do not stop blood pressure medicines or change doses without clinical advice. For urgent chest pain symptoms, call 999. [3]
Does Mounjaro reduce cardiovascular risk?
The evidence is promising, but it needs careful wording. GLP-1 receptor agonists as a class have been shown to reduce major adverse cardiovascular events in people with type 2 diabetes in cardiovascular outcome trials. A major meta-analysis reported a 14% relative reduction in MACE across GLP-1 receptor agonist trials. [4]
For tirzepatide specifically, the cardiovascular evidence has become stronger. In SURPASS-CVOT, published in the New England Journal of Medicine and summarised by the American College of Cardiology, tirzepatide was non-inferior to dulaglutide for a composite of cardiovascular death, myocardial infarction or stroke in adults with type 2 diabetes and atherosclerotic cardiovascular disease. The primary endpoint occurred in 12% of the tirzepatide group and 13% of the dulaglutide group after a median follow-up of four years. [5]
That is useful evidence, but it is not the same as saying Mounjaro is proven to prevent heart attacks in every person using it for weight loss. The SURPASS-CVOT population had type 2 diabetes and established atherosclerotic cardiovascular disease. A person using Mounjaro for weight management without diabetes or established cardiovascular disease is not the same population.
So the honest answer is: Mounjaro may support cardiovascular health indirectly through weight loss, blood pressure reduction and metabolic improvements, and there is direct cardiovascular outcome evidence in specific higher-risk groups. It should not be presented as a standalone heart-health treatment.
Does Mounjaro affect heart rate or cause heart problems?
Mounjaro can slightly increase heart rate in some people. In pooled type 2 diabetes studies, the UK SmPC reports a maximum mean increase in heart rate of 3 to 5 beats per minute across doses. In pooled weight-management studies, the average increase was around 3 beats per minute. [1]
A small average increase is not the same thing as a dangerous rhythm problem, but it is still worth taking seriously if you notice symptoms. Tell your prescriber if you develop persistent palpitations, fainting, unusual breathlessness, chest discomfort, or a resting heart rate that is consistently much higher than usual.
The same SmPC also reports that tirzepatide was not associated with excess cardiovascular events compared with pooled comparators in a meta-analysis of type 2 diabetes registration studies, and cardiovascular event rates were similar across placebo and tirzepatide in SURMOUNT-1, -2 and -3 weight-management studies. [1]
Urgent symptoms should not be managed as a “Mounjaro side effect” at home. Sudden chest pain or pressure that does not go away, pain spreading to the arm, jaw, neck, stomach or back, chest pain with sweating, sickness, light-headedness or shortness of breath may suggest a heart attack. Call 999. [3]
Does Mounjaro create plaque or clear plaque in arteries?
There is no good reason to say Mounjaro “creates plaque” in the arteries. That phrasing appears in search data, but it is not how the evidence is usually framed. There is also not enough evidence to promise that Mounjaro clears or reverses arterial plaque in an individual patient. Some GLP-1 medicines have cardiovascular benefits in higher-risk groups, and tirzepatide may improve several risk markers, but arterial plaque is influenced by many factors, including LDL cholesterol, blood pressure, smoking, diabetes, inflammation, age and family history.
If you have known coronary artery disease, previous heart attack, angina, stroke, peripheral arterial disease or high cholesterol, Mounjaro should sit within a broader cardiovascular plan. That plan may include statins, blood pressure treatment, antiplatelet treatment, diabetes care, smoking cessation, movement, nutrition and cardiology follow-up. Do not substitute weight loss treatment for established cardiovascular medication.
What should you monitor if you have high blood pressure?
If you have hypertension or take blood pressure tablets, it is sensible to monitor rather than guess. A simple home blood pressure log can help your GP or prescriber see whether readings are improving, staying stable or becoming too low.
- Take readings at a consistent time and record the date, time, reading and any symptoms.
- Do not over-check if it makes you anxious; agree a sensible frequency with your GP or prescriber.
- Record dizziness, faintness, palpitations, vomiting, diarrhoea, poor fluid intake or chest symptoms.
- Keep taking prescribed blood pressure medication unless a clinician tells you otherwise.
- Ask for a medication review if readings fall significantly, symptoms develop, or your GP has asked you to report changes.
Mounjaro can be part of a clinically supervised weight-management plan for some adults with high blood pressure, but the safest results come from joined-up care: accurate assessment, realistic monitoring, attention to side effects, and continued management of cardiovascular risk.
